BioSpace News Archive

The Japanese pharma’s financial numbers showed a drop in operating revenue as it signed a $300 million license and collaboration agreement with Protagonist Therapeutics.

Eton Pharmaceuticals today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today shared positive results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), conducted by Alexion, AstraZeneca Rare Disease.

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2023, which reflect strong pipeline acceleration, continued portfolio diversification, and momentum in our business.

Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held in Boston from February 3-7 in booth #408.

Eirion Therapeutics Inc. announced that the company will be participating in the 2024 International Master Course on Aging Science World Congress, taking place February 1 – 3, 2024, in Paris.

Treace Medical Concepts, Inc. today announced three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions were presented in a podium presentation at the 2024 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference.

Vor Bio announced that, effective as of January 29, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 50,000 shares of Vor Bio’s common stock and restricted stock units representing the right to receive an aggregate of 75,000 shares of Vor Bio’s common stock to five newly hired employees.

Fate Therapeutics, Inc. announced that on February 1, 2024 the Company granted restricted stock units representing 32,600 shares of its common stock to two newly-hired non-executive employees.